Bhave M, Jhaveri KL, Kaufman PA, Aftimos P, et al. Imlunestrant, an oral selective estrogen receptor degrader, in combination with HER2 directed therapy, with or without abemaciclib, in ER-positive, HER2-positive advanced breast cancer: results from the phase 1a/1b EMBER study. Breast Cancer Res 2025 Dec 21. doi: 10.1186/s13058-025-02168.
PMID: 41423595